SLN (Silence Therapeutics Corp) רווח למניה לשנה מתגלגלת

Silence Therapeutics (SLN) develops software algorithms to suppress gene malfunctions, monetizing its intellectual property through capital-expenditure-free licenses. The business's success relies on patent purity and the test results of drugs targeting heart disease. This chart on GURU.Markets illustrates the EPS TTM dynamics, which currently stand at 37.60. A steady cash flow is ensured by alliances with global pharmaceutical behemoths and FDA approval.
SLN (Silence Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To build a high-quality portfolio, I evaluate a business's ability to generate earnings per share. This indicator measures the percentage change in net income over a rolling year, reflecting the actual efficiency of operational activities. For Silence Therapeutics (SLN), this growth will become pivotal following the commercialization of its scalable, low-cost RNA platform. By analyzing the historical EPS YoY TTM delta, an investor can determine the exact moment the company transitions from the spending phase to profitability.